Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02450591 · ClinicalTrials.gov registry record · NA
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02450591: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02450591 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02450591, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.
Interventions
- DRUG Erlotinib
- OTHER Local Therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2017-12-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02450591
The ClinicalTrials.gov registry entry for NCT02450591 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT02450591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02450591 about?
NCT02450591 is a clinical study titled "Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations". This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.
What is the current status of trial NCT02450591?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2015-05-14. Estimated completion is 2017-12-11.
What interventions are being tested in trial NCT02450591?
The interventions under investigation include: Erlotinib (DRUG), Local Therapies (OTHER).
Who is sponsoring clinical trial NCT02450591?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.